Pioneering Off the Shelf, Allogeneic T‑Cell Immunotherapies

At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases.

Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.

Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need.

Our platform aims to leverage the unique biology of EBV T cells to channel the power of the immune system and has the potential to treat a wide range of diseases.

Atara is applying this one platform with no gene editing of the T-cell receptor to create a robust pipeline with the goal of developing treatments that improve the quality and longevity of patients' lives.

Key Features of Atara’s EBV T-Cell Platform

EBV T cells

EBV T cells naturally possess the following key characteristics:

  • Trafficking to the site of the disease
  • Specificity for disease targets with a low likelihood to harm normal cells
  • Ability to persist in the body long enough to fight disease

Allogeneic Donor Cells

Cells from donors are manufactured and stored in inventory with the goal of being readily available for patients with serious diseases

Next-Generation CAR T Technologies

Next-generation technologies designed to:

  • Improve persistence
  • Decrease cell exhaustion and death
  • Overcome the hostile tumor microenvironment
  • Target solid tumors

T-Cell Manufacturing and Delivery Platform

  • Robust, scalable manufacturing process
  • World-class facility
  • Designed for rapid delivery to patients within 3 days
  • Biologics-like cost-of-goods profile

A Differentiated Approach to Allogeneic Cell Therapy, with No Gene Editing of the T-Cell Receptor

Robust Allogeneic T-Cell Immunotherapy Pipeline

Three Strategic Priorities

Tabelecleucel (Tab-cel®) for EBV-driven diseases
ATA188 for progressive forms of multiple sclerosis (MS)
Next-generation CAR T for blood cancers and solid tumors
View Pipeline
Ayden
“Don’t give up. That’s the main thing.”
- Ayden Kidney transplant, PTLD Advocate
Mitch
“When somebody calls and says I’ve affected their life in a positive way—there’s not much better feeling than that. Especially knowing what people go through with this disease.”
- Mitch MS Advocate
Dan
“You have two options after you get a diagnosis: You can deny it or live it. I am choosing to live it. I am living the best I can with this disease.”
- Dan MS Advocate
Ola
“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”
- Ola Heart and kidney transplant, PTLD Advocate
Swapna
“I have found my passion in speaking and creating a larger platform—to use the experiences I have gone through to improve healthcare for all stakeholders.”
- Swapna Small intestine transplant, PTLD Advocate
Allison
“With my new lungs, I could walk up a flight of stairs without wheezing. I could breathe.”
- Allison Double lung transplant, PTLD Advocate
View Patient Stories

World-Class T-cell Research & Development Capabilities and Manufacturing Technologies

World-Class T-cell Research & Development Capabilities and Manufacturing Technologies1 World-Class T-cell Research & Development Capabilities and Manufacturing Technologies2 World-Class T-cell Research & Development Capabilities and Manufacturing Technologies3

Atara’s manufacturing technology is robust and designed to meet global regulatory standards and rapidly deliver products to patients from inventory within three days, with commercial validation activities near completion.

The Atara Research Center (ARC) houses the Company’s Translational and Pre-Clinical Sciences, Process Sciences, and Analytical Development teams. Its dedicated capabilities support our product pipeline and help drive innovation by leveraging our differentiated allogeneic cell therapy platform.

Our Fitzsimons facility in Denver is our hub for Process Development and Quality Control, with its capabilities facilitating the development, scale up, tech transfer and optimization of Atara’s advanced manufacturing processes for allogeneic cell therapies. In addition, select lot release testing of Atara’s drug products are performed at the site.

Latest News

November 23, 2022

Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference

View Press Release View All Press Releases
November 09, 2022

Atara Biotherapeutics to Participate at the Stifel Healthcare Conference

View Press Release
November 08, 2022

Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress

View Press Release